Question 1

How do you identify antibodies with high ADC potential?

Accepted Answer

Antibodies with high ADC potential typically combine strong target binding, efficient internalization, and potent cell-killing activity. By integrating internalization assays, cytotoxicity assays, and mechanism-of-action studies, researchers can identify and prioritize antibody candidates most likely to succeed in ADC development. This comprehensive screening strategy improves lead selection and reduces downstream development risk.

Question 2

What are the advantages of live-cell imaging-based ADC internalization assays?

Accepted Answer

Live-cell imaging-based internalization assays provide real-time visualization and quantification of antibody uptake in living cells. Key advantages include: time- and dose-dependent analysis in a single experiment, continuous monitoring for up to 72 hours, real-time kinetic data generation, high-throughput screening capability, and quantitative assessment of antibody internalization efficiency. These features enable rapid identification of antibodies with optimal ADC development potential.

Question 3

How does a toxin-based cytotoxicity assay support ADC development?

Accepted Answer

Toxin-based cytotoxicity assays evaluate antibody internalization by measuring the resulting cell-killing effect. Once the antibody-immunotoxin complex is internalized, the toxin inhibits protein synthesis and induces cell death. This approach provides a functional assessment of internalization while simulating the mechanism of action of ADC therapeutics. Key benefits include high specificity, functional confirmation of internalization, compatibility with hybridoma supernatants, broad species and antibody subtype applicability, and cost-effective early-stage screening.

Question 4

What are the advantages of the VHH-DT/MMAE assay compared with traditional DT-3C assays?

Accepted Answer

The VHH-DT/MMAE assay replaces the protein G domain used in traditional DT-3C assays with a high-affinity, highly specific VHH, reducing nonspecific interactions and improving assay performance. Benefits include higher sensitivity, improved signal-to-noise ratio, better reproducibility and consistency, no subclass-dependent bias, and accurate internalization measurement. These improvements help increase the success rate of identifying functional antibody leads.

Question 5

What types of ADC bioassays does ProBio offer?

Accepted Answer

ProBio offers a comprehensive ADC bioassay platform that supports multiple stages of ADC discovery, including antibody internalization assays (live-cell imaging based, pH-indicator based, temperature shift-based), cytotoxicity assays (DT3C, VHH-DT/MMAE), and bystander effect assays (co-culture assay, medium transfer assay). This diverse portfolio enables researchers to select the most appropriate assay format for their specific ADC discovery needs.

Question 6

Why choose ProBio for ADC internalization and cytotoxicity testing?

Accepted Answer

ProBio combines advanced assay technologies, extensive biological resources, and proven ADC expertise to accelerate candidate selection and optimization. Key differentiators include: 9 diverse assay formats for ADC evaluation, 80+ validated positive controls, 200+ tumor cell lines and 100+ engineered cell models, 200+ completed internalization projects, experience across dozens of validated targets including HER2, CD20, ROR1, and TROP2, and high-throughput and real-time assay platforms. These capabilities enable faster, more reliable identification of ADC candidates with strong therapeutic potential.

ADC Bioassay Service

Comprehensive ADC Bioassays: Internalization, Potency & Cytotoxicity Testing

Comprehensive Platform

Upgraded Screening Strategy

Proven Experience

Selecting High-Performance ADC Candidates with Confidence

Internalization Assays for ADC Candidate Screening

Live Cell Imaging-based Assay

Toxin-conjugated mAb-based Cytotoxicity Assay

Case Studies

Live-Cell Imaging Reveals Time- and Dose-Dependent Antibody Internalization.

Evaluating ADC Internalization Through Toxin-Induced Cytotoxicity.

Resources

Biologics Discovery Services Brochure

ADC Discovery Service

Accelerated ADC Development via Integrated Antibody Discovery Platform

In Vitro Pharmacology Solutions

Need Better ADC Candidates?

Related Services

Antibody Lead Optimization

Antibody Lead Generation

In Vitro Bioassay

Advanced Modalities Discovery

Developability Assessment

In Vivo Pharmacology

Frequently Asked Questions